Reuters logo
BRIEF-ViiV Healthcare announces positive phase III results for two-drug regimen of Dolutegravir and Rilpivirine
February 13, 2017 / 11:56 PM / 10 months ago

BRIEF-ViiV Healthcare announces positive phase III results for two-drug regimen of Dolutegravir and Rilpivirine

Feb 14 (Reuters) -

* ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

* ViiV Healthcare - in SWORD studies, two-drug regimen showed comparable efficacy to three- or four-drug regimens in virologically suppressed patients

* ViiV Healthcare - planning regulatory submissions for two-drug regimen as a single tablet in 2017 Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below